A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor
Status:
Completed
Trial end date:
2018-12-24
Target enrollment:
Participant gender:
Summary
An open-label, single oral dose of therapeutic Liporaxel and microdose 18F-Liporaxel
administration study was conducted in two breast cancer patients. Therapeutic dose of
Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).